Company news

Share this article:

Japanese drugmaker Astellas Pharma said it will set up a new company in Illinois in April to oversee the clinical development activities of its group as a whole. The transfer of Astellas' clinical development base, currently located in Japan, is aimed at speeding up decision-making and boosting market competitiveness, the company said. The new firm will be named Astellas Pharma Global Development Inc. Recently, a growing number of Japanese drugmakers have transferred their research and development bases to locations outside Japan, reflecting a slowdown in the domestic market and increased dependence on overseas sales.

Merck said that 44,000 of the roughly 47,000 people who registered for shares of a $4.85 billion settlement over the withdrawn painkiller Vioxx settlement have submitted all or some of the paperwork necessary for enrollment in the deal. Those who enrolled in the settlement by this past Friday could be eligible to receive an interim payment later this year.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

AstraZeneca takes on pediatricians

The American Academy of Pediatricians says an AstraZeneca drug for preemies should be used less often, and the drugmaker is fighting back with an ad campaign that says the new guidelines put too many at risk.

UK generic use soared in 2013

Generics made up almost 75% of prescriptions in the United Kingdom last year.

GSK refutes consumer spin-off rumor

The company refutes a Financial Times rumor that one was happening soonish.